Paragon Biosciences is an investor and incubator that grows and builds top biotechnology organizations. The company helps individuals to live healthier, longer lives. The company has a simple philosophy, first, listen to the needs of a patient, and then get to know the science related to the disease and finally come up with companies that focus their attention on unmet needs. Such a philosophy is behind the success of the company. Moreover, the company has a coherent drug development model which pace important medicine approvals. There are over 6,000 diseases in the world whose treatment is yet to be found. Paragon Biosciences vows to decrease that number as well as helping patients to live better, longer lives (https://www.dailyforexreport.com/jeff-aronins-company-paragon-biosciences-became-investment-incubator/).
According to Jeff Aronin, the company’s chairman, the company solves problems that have been considered unsolvable. The company creates organizations with regimented, targeted approaches that focus on particular medical areas. The company has developed such firms like Castle Creek, Harmony Biosciences, Decade, and Precision BP. The company has a wide investigational drugs pipeline in four therapeutic places that are tested across the family of companies in clinical trials. The company is proud of developing opportunities where other firms have not. Paragon Biosciences overcome and embrace issues connected to delivering significant medicines to patients who really need them.
Jeff Aronin is the CEO and chairman of Paragon Biosciences. Jeff has served in these positions since 2010. Moreover, Jeff has also been non-executive chairman of various Paragon portfolios organizations such as Harmony Biosciences, Castle Creek Pharmaceuticals and much more. From 2000 to 2009, Jeff served the CEO and president to Ovation Pharmaceuticals Inc., a company he established in. Later the Ovarian pharmaceuticals were acquired by Lundbeck Inc.
Jeff Aronin also served as Lundbeck’s CEO and president during the time of Ovarian pharmaceutical’s acquirement and integration. Moreover, Jeff Aronin has gained CEO experience after working and leading various international biopharmaceutical firms. He also has knowledge of finance, business development, brand marketing and many more. Besides, he has experience in structuring as well as the execution of calculated business transactions such as mergers and acquisition